Within three decades, anti-angiogenic therapy has rapidly evolved into an integral
component of current standard anti-cancer treatment. Anti-angiogenic therapy has fulfilled a
number of its earlier proposed promises. The universality of this approach is demonstrated
by the broad spectrum of malignant and benign tumor entities, as well as non-neoplastic
diseases, that are currently treated with anti-angiogenic agents. In contrast to tumor cell
targeting therapies, the development of acquired drug resistance (eg, via mutations in …